Cytori Therapeutics has appointed Clyde W. Shores as Executive Vice President of Marketing & Sales where he will lead the Company's strategic marketing initiatives for all product lines around the world.
Specifically, Mr. Shores will spearhead Cytori's preparations for the formal launch of the next-generation Celution® One System for hospital based sales.
Mr. Shores will also oversee strategy and initiatives to drive adoption and use of Cytori's existing products, including the Celution® 800 and PureGraft™ Systems as well as StemSource® cell and tissue banking, and will lay the foundation for new regional and indication-based claims for our existing products in both the EU and the US.
"Cytori has undergone an extensive search for the ideal leader of its marketing team," said Marc H. Hedrick, President of Cytori Therapeutics.
Hedrick continued, "With his background in cell therapy, medical devices and pharmaceuticals, Clyde is uniquely qualified to drive our marketing efforts as we continue to lead the way in regenerative medicine. His entrepreneurial spirit, combined with broad experience with high growth products and industries, will allow him to integrate seamlessly with the existing culture at Cytori and add tremendous value to our marketing and sales teams."
Mr. Shores has 27 years experience in medical marketing and sales and has been involved in the launch and marketing of multiple innovative medical products such as Amgen's revolutionary Neupogen®.
Most recently, Mr. Shores served as Vice President of Global Marketing for Baxter International's Renal Business. Prior to Baxter, Mr. Shores worked for Abbott Laboratories, Amgen, Prometheus Laboratories and deCODE Genetics.
During his 9 years at Amgen and tenure with other companies, he developed a fundamental understanding of the potential for stem cell pharmaceuticals and devices, the commercialization of innovative therapeutics and the marketing and sales capabilities required to achieve significant revenue growth in global markets.